Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026
Altimmune will present new clinical and preclinical data on pemvidutide at AASLD The Liver Meeting 2026, November 5-9 in Denver. The 48-week IMPACT Phase 2b data in MASH showed concurrent reductions in liver stiffness, ELF score, liver fat and ALT versus placebo, with mild-to-moderate GI tolerability and fewer discontinuations than placebo despite no dose titration. New preclinical data showed a significant reduction in alcohol intake in a hamster model, supporting further study of pemvidutide in alcohol use disorder and alcohol-associated liver disease.
Key figures
- Drug Name
- pemvidutide
- Phase Of Trial
- Phase 2b
- Trial duration weeks
- 48
- Impact trial enrollment
- 212
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.